1.	Vaccine Treatment for Hormone Refractory Prostate Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 19 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NLG0103, 398-04FB, NCT00105053
2.	Vaccine Treatment for Advanced Malignant Melanoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NLG0104, OBA#0404-640, NCT00300612
3.	A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: Under 21 Sponsor: Other Protocol IDs: 22053-CHESAT, NCT00703222
4.	Phase II Study of Active Intralymphatic Immunotherapy With Interferon Alfa-Treated Allogeneic Tumor Cells Plus Sargramostim (GM-CSF) and Cyclophosphamide in Patients With Advanced Pancreatic Adenocarcinoma (Summary Last Modified 06/2001) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: SVMC-ONC-222P, NCI-V96-0886, NCT00002773
5.	Phase II Pilot Study of Cyclophosphamide and Active Intralymphatic Immunotherapy With a Vaccine Containing Interferon alfa or Interferon gamma-Treated Tumor Cells Followed By Sargramostim (GM-CSF) in Patients With Advanced Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: SVMC-ONC-222, NCI-V91-0075, NCT00002475
6.	Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 to 80 Sponsor: NCI, Other Protocol IDs: CDR0000410830, R21CA091624, UKMC-IRB-0391-F2R, UKMC-CTRF-G-01-009, NCT00103116
7.	Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: MCC-14744, P30CA076292, NIH-OBA-0608-801, MCC-104490, MCC-0534-NE, NCT00601796
8.	Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: CTN-0505, UKIRB 06-0716-F3R, ULIRB 065.07, CIRB 1079747, NCT00654030
9.	Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000630404, MAYO-MC0554, MAYO-06-004659, MC0554, NCT00814892
10.	Immunotherapy with BCG with or without Irradiated Allogeneic Cells for Stage I Lung Carcinoma Phase: No phase specified Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: NCI-LUN-1
11.	Allogeneic Tumor Cells During Intensive Maintenance Chemotherapy After Induction with ARA-C/ADR for Acute Myelocytic Leukemia Phase: No phase specified Type: Treatment Status: Closed Age: Under 70 Sponsor: Protocol IDs: RPMI-DMA-970701, NCI-D78-026-209
12.	Surgical Resection, Chemotherapy with CTX/ADR, Radiotherapy and Immunotherapy with BCG and Tumor Cells for Neuroblastoma Phase: No phase specified Type: Treatment Status: Closed Age: under 18 Sponsor: Protocol IDs: SJCRH-NB-1, SJCRH-NB-74
13.	Chemotherapy plus BCG Immunotherapy with or without Allogeneic Tumor Cells for Acute Myeloid Leukemia Phase: No phase specified Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: SWE-LGMS-AML-1
14.	Chemotherapy with Adriamycin/Cyclophosphamide with or without BCG/Tumor Cell Vaccine Immunotherapy for Lung Carcinoma Phase: No phase specified Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: UARIZ-IIIB
15.	Chemotherapy with ADR, MTX with & without Adjuvant Immunotherapy with BCG & Allogeneic Tumor Cell Vaccine in Skeletal & Soft Tissue Sarcoma Phase: No phase specified Type: Treatment Status: Closed Age: 5 to 70 Sponsor: Protocol IDs: UCLA-SAR-1